Mostrar el registro sencillo del ítem
dc.contributor.author | Romero-Miguel, Diego | |
dc.contributor.author | Casquero-Veiga, Marta | |
dc.contributor.author | Lamanna-Rama, Nicolás | |
dc.contributor.author | Torres-Sánchez, Sonia | |
dc.contributor.author | MacDowell, Karina S | |
dc.contributor.author | García-Partida, José A | |
dc.contributor.author | Santa-Marta, Cristina | |
dc.contributor.author | Berrocoso, Esther | |
dc.contributor.author | Leza, Juan C | |
dc.contributor.author | Desco, Manuel | |
dc.contributor.author | Soto-Montenegro, María Luisa | |
dc.date.accessioned | 2024-07-09T09:58:12Z | |
dc.date.available | 2024-07-09T09:58:12Z | |
dc.date.issued | 2024-01-08 | |
dc.identifier.citation | Transl Psychiatry. 2024 Jan 8;14(1):14. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/20319 | |
dc.description.abstract | Schizophrenia is a chronic neurodevelopmental disorder with an inflammatory/prooxidant component. N-acetylcysteine (NAC) has been evaluated in schizophrenia as an adjuvant to antipsychotics, but its role as a preventive strategy has not been sufficiently explored. We aimed to evaluate the potential of NAC administration in two-time windows before the onset of symptoms in a schizophrenia-like maternal immune stimulation (MIS) rat model. Pregnant Wistar rats were injected with Poly I:C or Saline on gestational day (GD) 15. Three different preventive approaches were evaluated: 1) NAC treatment during periadolescence in the offspring (from postnatal day [PND] 35 to 49); 2) NAC treatment during pregnancy after MIS challenge until delivery (GD15-21); and 3) NAC treatment throughout all pregnancy (GD1-21). At postnatal day (PND) 70, prepulse inhibition (PPI) and anxiety levels were evaluated. In vivo magnetic resonance (MR) imaging was acquired on PND100 to assess structural changes in gray and white matter, and brain metabolite concentrations. Additionally, inflammation and oxidative stress (IOS) markers were measured ex vivo in selected brain regions. MIS offspring showed behavioral, neuroanatomical, and biochemical alterations. Interestingly, NAC treatment during periadolescence prevented PPI deficits and partially counteracted some biochemical imbalances. Moreover, NAC treatments during pregnancy not only replicated the beneficial outcomes reported by the treatment in periadolescence, but also prevented some neuroanatomical deficits, including reductions in hippocampal and corpus callosum volumes. This study suggests that early reduction of inflammation and prooxidation could help prevent the onset of schizophrenia-like symptoms, supporting the importance of anti-IOS compounds in ameliorating this disorder. | es_ES |
dc.description.sponsorship | MLS was supported by the Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III (project number PI17/01766, and grant number BA21/00030), co-financed by the European Regional Development Fund (ERDF), “A way to make Europe”; project PID2021-128862OB-I00 funded by MCIN /AEI /10.13039/501100011033 / FEDER, UE, CIBER de Salud Mental - Instituto de Salud Carlos III (project number CB07/ 09/0031); Delegación del Gobierno para el Plan Nacional sobre Drogas (project number 2017/085), Delegación del Gobierno para el Plan Nacional sobre Drogas correspondiente a fondos del Mecanismo de Recuperación, Transformación y Resiliencia de la Unión Europea (EXP2022/008917); and Fundación Alicia Koplowitz. DRM was supported by Consejería de Educación e investigación, Comunidad de Madrid, co-funded by the European Social Fund “Investing in your future” (grant, PEJD-2018-PRE/BMD-7899). MCV was supported by a predoctoral grant from Fundación Tatiana Pérez de Guzmán el Bueno. NLR was supported by the Instituto de investigación Sanitaria Gregorio Marañón, “Programa Intramural de Impulso a la I + D + I 2019”. MD work was supported by Ministerio de Ciencia e Innovación (MCIN) and Instituto de Salud Carlos III (PT20/00044). The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN) and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-0505). EBD, JAG-P and ST-S work was supported by the “Fondo Europeo de Desarrollo Regional” (FEDER)-UE “A way to build Europe” from the “Ministerio de Economía y Competitividad” (RTI2018-099778-B-I00); from the “Plan Nacional sobre Drogas, Ministerio de Sanidad, Consumo y Bienestar Social” (2019I041); from the “Ministerio de Salud-Instituto de Salud Carlos III” (PI18/01691); from the “Programa Operativo de Andalucía FEDER, Iniciativa Territorial Integrada ITI 2014-2020 Consejería Salud y Familias, Junta de Andalucía” (PI-0080-2017, PI-0009-2017), "Consejería de Salud y Familias, Junta de Andalucía" (PI-0134-2018 and PEMP-0008-2020); from the "Consejería de Transformación Económica, Industria, Conocimiento y Universidad, Junta de Andalucía" (P20_00958 and CTS-510); from the CEIMAR (CEIJ-003); from the “Instituto de Investigación e Innovación en Ciencias Biomédicas de Cádiz-INiBICA” (LI19/06IN-CO22; IN-C09); from the “CIBERSAM”: CIBER-Consorcio Centro de Investigación Biomédica en Red- (CB07/09/0033), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 955684. JCL was supported by the Ministerio de Economía y Competitividad, MINECO-EU-FEDER (SAF2016-75500-R) and Ministerio de Ciencia e Innovación (PID2019-109033RB-I00). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Nature Publishing Group | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject.mesh | Acetylcysteine | es_ES |
dc.subject.mesh | Schizophrenia | es_ES |
dc.subject.mesh | Female | es_ES |
dc.subject.mesh | Pregnancy | es_ES |
dc.subject.mesh | Rats | es_ES |
dc.subject.mesh | Animals | es_ES |
dc.subject.mesh | Rats, Wistar | es_ES |
dc.subject.mesh | Poly I-C | es_ES |
dc.subject.mesh | Inflammation | es_ES |
dc.title | N-acetylcysteine during critical neurodevelopmental periods prevents behavioral and neurochemical deficits in the Poly I:C rat model of schizophrenia. | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 38191622 | es_ES |
dc.format.volume | 14 | es_ES |
dc.format.number | 1 | es_ES |
dc.format.page | 14 | es_ES |
dc.identifier.doi | 10.1038/s41398-023-02652-7 | es_ES |
dc.contributor.funder | Ministerio de Ciencia e Innovación (España) | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | es_ES |
dc.contributor.funder | Plan Nacional de Drogas (España) | es_ES |
dc.contributor.funder | Fundación Alicia Koplowitz | es_ES |
dc.contributor.funder | Comunidad de Madrid (España) | es_ES |
dc.contributor.funder | Instituto de Investigación Sanitaria Gregorio Marañón | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 2158-3188 | es_ES |
dc.relation.publisherversion | 10.1038/s41398-023-02652-7 | es_ES |
dc.identifier.journal | Translational psychiatry | es_ES |
dc.repisalud.orgCNIC | CNIC::Unidades técnicas::Imagen Avanzada | es_ES |
dc.repisalud.institucion | CNIC | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PI17/01766 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/BA21/00030 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PID2021-128862OB-I00 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/MCIN/AEI/10.13039/501100011033 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/CB07/09/0031 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/2017/085 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/EXP2022/008917 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PEJD-2018-PRE/BMD-7899 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PT20/00044 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/SEV-2015-0505 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/RTI2018-099778-B-I00 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/2019I041 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PI18/01691 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PI-0080-2017 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PI-0009-2017 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PI-0134-2018 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PEMP-0008-2020 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/P20/00958 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/LI19/06IN-CO22 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/CB07/09/0033 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/SAF2016-75500-R | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PID2019-109033RB-I00 | es_ES |